{"organizations": [], "uuid": "81a3c0045ccb1582d3af3755460c2e798293028b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-syneos-health-reports-q-gaap-dilut/brief-syneos-health-reports-q-gaap-diluted-loss-per-share-of-0-14-idUSFWN1QI0T7", "country": "US", "domain_rank": 408, "title": "BRIEF-Syneos Health Reports Q$ GAAP Diluted Loss Per Share Of $0.14", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-28T13:55:00.000+02:00", "replies_count": 0, "uuid": "81a3c0045ccb1582d3af3755460c2e798293028b"}, "author": "", "url": "https://www.reuters.com/article/brief-syneos-health-reports-q-gaap-dilut/brief-syneos-health-reports-q-gaap-diluted-loss-per-share-of-0-14-idUSFWN1QI0T7", "ord_in_thread": 0, "title": "BRIEF-Syneos Health Reports Q$ GAAP Diluted Loss Per Share Of $0.14", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-syneos health reports", "sentiment": "negative"}, {"name": "reuters) - syneos health inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 28, 2018 / 11:55 AM / Updated 13 minutes ago BRIEF-Syneos Health Reports Q$ GAAP Diluted Loss Per Share Of $0.14 Reuters Staff Feb 28 (Reuters) - Syneos Health Inc: * SYNEOS HEALTH INC - GAAP DILUTED LOSS PER SHARE OF $0.14 FOR THE FOURTH QUARTER‍​ * SYNEOS HEALTH INC - COMBINED COMPANY ADJUSTED DILUTED EPS OF $0.70 FOR THE FOURTH QUARTER‍​ * SYNEOS HEALTH INC - BOARD OF DIRECTORS AUTHORIZED $250.0 MILLION STOCK REPURCHASE PROGRAM * SYNEOS HEALTH INC - QTRLY TOTAL REVENUE $1.08 BILLION VERSUS $406.1 MILLION * SYNEOS HEALTH INC - SEES Q1 GAAP DILUTED EPS, LOSS OF $0.03 TO EPS OF $ 0.04 ‍​ * SYNEOS HEALTH INC - SEES Q1 ADJUSTED DILUTED EPS $ 0.54 TO $ 0.60 * SYNEOS HEALTH INC - SEES FY 2018 GAAP DILUTED EPS $ 0.63 TO $ 0.89 ‍​ * SYNEOS HEALTH INC - SEES FY 2018 ADJUSTED DILUTED EPS $ 2.68 TO $ 2.94 * SYNEOS HEALTH INC - SEES Q1 NET SERVICE REVENUE $ 751.0 MILLION TO $ 781.0 ‍​MILLION * SYNEOS HEALTH INC - DUE TO ENACTMENT OF TAX ACT, IN Q4 2017 CO RECORDED $94.4 MILLION NON-CASH CHARGE TO INCOME TAX EXPENSE FOR U.S. GAAP PURPOSES​ * SYNEOS HEALTH INC - SEES FY 2018 NET SERVICE REVENUE $3,229.5 MILLION VERSUS $3,334.5 MILLION * SYNEOS HEALTH INC - ANTICIPATE 2018 EFFECTIVE TAX RATE WILL DECREASE TO 30.0% - 32.0%, WHICH TAKES INTO ACCOUNT EFFECT OF THE ENACTMENT OF THE TAX ACT‍​ * SYNEOS HEALTH - ‍COMBINED COMPANY CLINICAL SOLUTIONS BACKLOG GREW 6.6% TO $3.80 BILLION AS OF DEC 31, 2017, VERSUS $3.56 BILLION AS OF DEC 31, 2016​ * SYNEOS HEALTH INC - ‍EXPECT ABOUT $1.88 BILLION OF CLINICAL SOLUTIONS BACKLOG AT DEC 31, 2017 TO BE RECOGNIZED AS REVENUE DURING 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-28T13:55:00.000+02:00", "crawled": "2018-02-28T14:12:50.042+02:00", "highlightTitle": ""}